Research
Effects of intensive blood pressure lowering on the progression of chronic kidney disease: a systematic review and meta-analysis
Jicheng Lv, Parya Ehteshami, Mark J. Sarnak, Hocine Tighiouart, Min Jun, Toshiharu Ninomiya, Celine Foote, Anthony Rodgers, Hong Zhang, Haiyan Wang, Giovanni F.M. Strippoli and Vlado Perkovic
CMAJ August 06, 2013 185 (11) 949-957; DOI: https://doi.org/10.1503/cmaj.121468
Jicheng Lv
The George Institute for Global Health (Lv, Ehteshami, Jun, Foote, Rodgers, Perkovic), The University of Sydney, Sydney, Australia; Renal Division, Department of medicine (Lv, Zhang, Wang), Peking University First Hospital, Beijing, China; Tufts Medical Center (Sarnak, Tighiouart), Boston, Mass.; the Department of Medicine and Clinical Science Graduate School of Medical Sciences (Ninomiya), Kyushu University, Japan; the Centre for Kidney Research (Strippoli), The Children’s Hospital at Westmead, School of Public Health, The University of Sydney, Sydney, Australia; the Department of Pharmacology and Epidemiology (Strippoli), Mario Negri Sud Consortium, S Maria Imbaro, Chieti, Italy; and DIAVERUM Medical-Scientific Office (Strippoli), Lund, Sweden
MD PhDParya Ehteshami
The George Institute for Global Health (Lv, Ehteshami, Jun, Foote, Rodgers, Perkovic), The University of Sydney, Sydney, Australia; Renal Division, Department of medicine (Lv, Zhang, Wang), Peking University First Hospital, Beijing, China; Tufts Medical Center (Sarnak, Tighiouart), Boston, Mass.; the Department of Medicine and Clinical Science Graduate School of Medical Sciences (Ninomiya), Kyushu University, Japan; the Centre for Kidney Research (Strippoli), The Children’s Hospital at Westmead, School of Public Health, The University of Sydney, Sydney, Australia; the Department of Pharmacology and Epidemiology (Strippoli), Mario Negri Sud Consortium, S Maria Imbaro, Chieti, Italy; and DIAVERUM Medical-Scientific Office (Strippoli), Lund, Sweden
BScMark J. Sarnak
The George Institute for Global Health (Lv, Ehteshami, Jun, Foote, Rodgers, Perkovic), The University of Sydney, Sydney, Australia; Renal Division, Department of medicine (Lv, Zhang, Wang), Peking University First Hospital, Beijing, China; Tufts Medical Center (Sarnak, Tighiouart), Boston, Mass.; the Department of Medicine and Clinical Science Graduate School of Medical Sciences (Ninomiya), Kyushu University, Japan; the Centre for Kidney Research (Strippoli), The Children’s Hospital at Westmead, School of Public Health, The University of Sydney, Sydney, Australia; the Department of Pharmacology and Epidemiology (Strippoli), Mario Negri Sud Consortium, S Maria Imbaro, Chieti, Italy; and DIAVERUM Medical-Scientific Office (Strippoli), Lund, Sweden
MDHocine Tighiouart
The George Institute for Global Health (Lv, Ehteshami, Jun, Foote, Rodgers, Perkovic), The University of Sydney, Sydney, Australia; Renal Division, Department of medicine (Lv, Zhang, Wang), Peking University First Hospital, Beijing, China; Tufts Medical Center (Sarnak, Tighiouart), Boston, Mass.; the Department of Medicine and Clinical Science Graduate School of Medical Sciences (Ninomiya), Kyushu University, Japan; the Centre for Kidney Research (Strippoli), The Children’s Hospital at Westmead, School of Public Health, The University of Sydney, Sydney, Australia; the Department of Pharmacology and Epidemiology (Strippoli), Mario Negri Sud Consortium, S Maria Imbaro, Chieti, Italy; and DIAVERUM Medical-Scientific Office (Strippoli), Lund, Sweden
MSMin Jun
The George Institute for Global Health (Lv, Ehteshami, Jun, Foote, Rodgers, Perkovic), The University of Sydney, Sydney, Australia; Renal Division, Department of medicine (Lv, Zhang, Wang), Peking University First Hospital, Beijing, China; Tufts Medical Center (Sarnak, Tighiouart), Boston, Mass.; the Department of Medicine and Clinical Science Graduate School of Medical Sciences (Ninomiya), Kyushu University, Japan; the Centre for Kidney Research (Strippoli), The Children’s Hospital at Westmead, School of Public Health, The University of Sydney, Sydney, Australia; the Department of Pharmacology and Epidemiology (Strippoli), Mario Negri Sud Consortium, S Maria Imbaro, Chieti, Italy; and DIAVERUM Medical-Scientific Office (Strippoli), Lund, Sweden
PhDToshiharu Ninomiya
The George Institute for Global Health (Lv, Ehteshami, Jun, Foote, Rodgers, Perkovic), The University of Sydney, Sydney, Australia; Renal Division, Department of medicine (Lv, Zhang, Wang), Peking University First Hospital, Beijing, China; Tufts Medical Center (Sarnak, Tighiouart), Boston, Mass.; the Department of Medicine and Clinical Science Graduate School of Medical Sciences (Ninomiya), Kyushu University, Japan; the Centre for Kidney Research (Strippoli), The Children’s Hospital at Westmead, School of Public Health, The University of Sydney, Sydney, Australia; the Department of Pharmacology and Epidemiology (Strippoli), Mario Negri Sud Consortium, S Maria Imbaro, Chieti, Italy; and DIAVERUM Medical-Scientific Office (Strippoli), Lund, Sweden
MD PhDCeline Foote
The George Institute for Global Health (Lv, Ehteshami, Jun, Foote, Rodgers, Perkovic), The University of Sydney, Sydney, Australia; Renal Division, Department of medicine (Lv, Zhang, Wang), Peking University First Hospital, Beijing, China; Tufts Medical Center (Sarnak, Tighiouart), Boston, Mass.; the Department of Medicine and Clinical Science Graduate School of Medical Sciences (Ninomiya), Kyushu University, Japan; the Centre for Kidney Research (Strippoli), The Children’s Hospital at Westmead, School of Public Health, The University of Sydney, Sydney, Australia; the Department of Pharmacology and Epidemiology (Strippoli), Mario Negri Sud Consortium, S Maria Imbaro, Chieti, Italy; and DIAVERUM Medical-Scientific Office (Strippoli), Lund, Sweden
MDAnthony Rodgers
The George Institute for Global Health (Lv, Ehteshami, Jun, Foote, Rodgers, Perkovic), The University of Sydney, Sydney, Australia; Renal Division, Department of medicine (Lv, Zhang, Wang), Peking University First Hospital, Beijing, China; Tufts Medical Center (Sarnak, Tighiouart), Boston, Mass.; the Department of Medicine and Clinical Science Graduate School of Medical Sciences (Ninomiya), Kyushu University, Japan; the Centre for Kidney Research (Strippoli), The Children’s Hospital at Westmead, School of Public Health, The University of Sydney, Sydney, Australia; the Department of Pharmacology and Epidemiology (Strippoli), Mario Negri Sud Consortium, S Maria Imbaro, Chieti, Italy; and DIAVERUM Medical-Scientific Office (Strippoli), Lund, Sweden
MD PhDHong Zhang
The George Institute for Global Health (Lv, Ehteshami, Jun, Foote, Rodgers, Perkovic), The University of Sydney, Sydney, Australia; Renal Division, Department of medicine (Lv, Zhang, Wang), Peking University First Hospital, Beijing, China; Tufts Medical Center (Sarnak, Tighiouart), Boston, Mass.; the Department of Medicine and Clinical Science Graduate School of Medical Sciences (Ninomiya), Kyushu University, Japan; the Centre for Kidney Research (Strippoli), The Children’s Hospital at Westmead, School of Public Health, The University of Sydney, Sydney, Australia; the Department of Pharmacology and Epidemiology (Strippoli), Mario Negri Sud Consortium, S Maria Imbaro, Chieti, Italy; and DIAVERUM Medical-Scientific Office (Strippoli), Lund, Sweden
MD PhDHaiyan Wang
The George Institute for Global Health (Lv, Ehteshami, Jun, Foote, Rodgers, Perkovic), The University of Sydney, Sydney, Australia; Renal Division, Department of medicine (Lv, Zhang, Wang), Peking University First Hospital, Beijing, China; Tufts Medical Center (Sarnak, Tighiouart), Boston, Mass.; the Department of Medicine and Clinical Science Graduate School of Medical Sciences (Ninomiya), Kyushu University, Japan; the Centre for Kidney Research (Strippoli), The Children’s Hospital at Westmead, School of Public Health, The University of Sydney, Sydney, Australia; the Department of Pharmacology and Epidemiology (Strippoli), Mario Negri Sud Consortium, S Maria Imbaro, Chieti, Italy; and DIAVERUM Medical-Scientific Office (Strippoli), Lund, Sweden
MDGiovanni F.M. Strippoli
The George Institute for Global Health (Lv, Ehteshami, Jun, Foote, Rodgers, Perkovic), The University of Sydney, Sydney, Australia; Renal Division, Department of medicine (Lv, Zhang, Wang), Peking University First Hospital, Beijing, China; Tufts Medical Center (Sarnak, Tighiouart), Boston, Mass.; the Department of Medicine and Clinical Science Graduate School of Medical Sciences (Ninomiya), Kyushu University, Japan; the Centre for Kidney Research (Strippoli), The Children’s Hospital at Westmead, School of Public Health, The University of Sydney, Sydney, Australia; the Department of Pharmacology and Epidemiology (Strippoli), Mario Negri Sud Consortium, S Maria Imbaro, Chieti, Italy; and DIAVERUM Medical-Scientific Office (Strippoli), Lund, Sweden
MD PhDVlado Perkovic
The George Institute for Global Health (Lv, Ehteshami, Jun, Foote, Rodgers, Perkovic), The University of Sydney, Sydney, Australia; Renal Division, Department of medicine (Lv, Zhang, Wang), Peking University First Hospital, Beijing, China; Tufts Medical Center (Sarnak, Tighiouart), Boston, Mass.; the Department of Medicine and Clinical Science Graduate School of Medical Sciences (Ninomiya), Kyushu University, Japan; the Centre for Kidney Research (Strippoli), The Children’s Hospital at Westmead, School of Public Health, The University of Sydney, Sydney, Australia; the Department of Pharmacology and Epidemiology (Strippoli), Mario Negri Sud Consortium, S Maria Imbaro, Chieti, Italy; and DIAVERUM Medical-Scientific Office (Strippoli), Lund, Sweden
MD PhDData supplements
Online Appendices
- Appendix 1 : Searching strategy
- Appendix 2 : Risk of bias
- Appendix 3 : Begg's funnel plot for the assessment of publication bias in studies examining the effect of intensive blood pressure lowering on kidney failure
- Appendix 4 : Subgroup analysis of intensive blood pressure lowering on kidney failure
- Appendix 5 : Intensive blood pressure lowering and cardiovascular outcomes in patients with chronic kidney disease
Related Articles
- Hildebrand, A. M., & Garg, A. X. (2013). Blood pressure targets in chronic kidney disease: Does proteinuria dictate how low we go?. CMAJ, 185(11), 941-942. Accessed April 23, 2024. https://doi.org/10.1503/cmaj.130168.
- (2013). Highlights. CMAJ, 185(11), 935. Accessed April 23, 2024. Retrieved from http://www.cmaj.ca/content/185/11/935.
In this issue
Article tools
Respond to this article
Effects of intensive blood pressure lowering on the progression of chronic kidney disease: a systematic review and meta-analysis
Jicheng Lv, Parya Ehteshami, Mark J. Sarnak, Hocine Tighiouart, Min Jun, Toshiharu Ninomiya, Celine Foote, Anthony Rodgers, Hong Zhang, Haiyan Wang, Giovanni F.M. Strippoli, Vlado Perkovic
CMAJ Aug 2013, 185 (11) 949-957; DOI: 10.1503/cmaj.121468
Effects of intensive blood pressure lowering on the progression of chronic kidney disease: a systematic review and meta-analysis
Jicheng Lv, Parya Ehteshami, Mark J. Sarnak, Hocine Tighiouart, Min Jun, Toshiharu Ninomiya, Celine Foote, Anthony Rodgers, Hong Zhang, Haiyan Wang, Giovanni F.M. Strippoli, Vlado Perkovic
CMAJ Aug 2013, 185 (11) 949-957; DOI: 10.1503/cmaj.121468
Jump to section
Related Articles
Cited By...
- Quality of systematic reviews supporting the 2017 ACC/AHA and 2018 ESC/ESH guidelines for the management of hypertension
- Thinking Outside the Box: Novel Kidney Protective Strategies in Kidney Transplantation
- Impact of point-of-care screening for hypertension, diabetes and progression of chronic kidney disease in rural Manitoba Indigenous communities
- Effect of intensive blood pressure on the progression of non-diabetic chronic kidney disease at varying degrees of proteinuria
- Effects of Intensive Blood Pressure Control in Patients with and without Albuminuria: Post Hoc Analyses from SPRINT
- Intensive Blood Pressure Lowering Should Be the Goal for Most Individuals at High Risk of Cardiovascular Disease Irrespective of Albuminuria
- Progress in using the electronic health record to improve primary care
- Chronic kidney disease in adults: assessment and management
- Effects of antihypertensives, lipid-modifying drugs, glycaemic control drugs and sodium bicarbonate on the progression of stages 3 and 4 chronic kidney disease in adults: a systematic review and meta-analysis
- 2019 ACC/AHA Guideline on the Primary Prevention of Cardiovascular Disease: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines
- 2019 ACC/AHA Guideline on the Primary Prevention of Cardiovascular Disease: Executive Summary: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines
- Improving coding and primary care management for patients with chronic kidney disease: an observational controlled study in East London
- Intensive Blood Pressure Targets and Kidney Disease
- Hypertension Management in Diabetes: 2018 Update
- The National CKD Audit: a primary care condition that deserves more attention
- 2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults: Executive Summary: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines
- 2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines
- 2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults: Executive Summary: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines
- 2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines
- Effects of Intensive BP Control in CKD
- 2017 ACC/AHA/HFSA Focused Update of the 2013 ACCF/AHA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Failure Society of America
- 2017 ACC/AHA/HFSA Focused Update of the 2013 ACCF/AHA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Failure Society of America
- Time-Varying Association of Individual BP Components with eGFR in Late-Stage CKD
- Etude SPRINT : Donnees probantes sur les cibles precises de la tension arterielle
- SPRINT to evidence for specific blood pressure targets
- Results and lessons from the Spironolactone To Prevent Cardiovascular Events in Early Stage Chronic Kidney Disease (STOP-CKD) randomised controlled trial
- Treating hypertension in patients with medical comorbidities
- Assessing the Validity of Surrogate Outcomes for ESRD: A Meta-Analysis
- Modification of the Relationship Between Blood Pressure and Renal Albumin Permeability by Impaired Excretory Function and Diabetes
- Blood Pressure and Risk of All-Cause Mortality in Advanced Chronic Kidney Disease and Hemodialysis: The Chronic Renal Insufficiency Cohort Study
- Blood pressure targets in chronic kidney disease: Does proteinuria dictate how low we go?